SB Singh, Poornima Mansoria and Savita Sharma
The global pandemic of the Corona virus disease (COVID-19) has caused widespread morbidity and mortality globally. The complicated pathophysiology of COVID-19 and lack of a single therapy have made management a significant issue. Through comprehensive pharmacological, toxicological, and clinical research, AYUSH-64, a poly-herbal formulation developed by CCRAS, ministry of AYUSH, government of India, has demonstrated both its safety and effectiveness in treating infective febrile illnesses like malaria and influenza. Four components in AYUSH-64 include antiviral, immunomodulatory, anti-inflammatory, antipyretic, and anti-inflammatory properties. In COVID-19, it stops the inflammatory responses that lead to substantial morbidity. The government of India has also included AYUSH-64 in the National COVID management protocol based on Ayurveda and Yoga for asymptomatic and mild cases of COVID-19. The study summarizes the therapeutic potential of AYUSH-64 on the basis of clinical trials conducted in India on COVID-19.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 